Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine.

Kriangkrai Tawinprai,Taweegrit Siripongboonsitti,Thachanun Porntharukchareon,Kasiruck Wittayasak,Nawarat Thonwirak,Kamonwan Soonklang,Gaidganok Sornsamdang,Chirayu Auewarakul,Nithi Mahanonda

Expert review of vaccines（2022）

引用 4|浏览3

暂无评分

摘要

A third vaccination with the heterologous vaccine, BBIBP-CorV, AZD1222, or BNT162b2, can elicit a robust immune response, without serious adverse events in participants fully vaccinated with the CoronaVac vaccine.

查看译文

关键词

AZD1222,BBIBP-CorV,BNT162b2,ChAdOx1,booster dose,immunogenicity,reactogenicity,third dose

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要